Viviane C Campos Selected Research

Pituitary Dwarfism

1/2021	Reduced fibroblast growth factor 21 and β-Klotho secretion in untreated congenital isolated GH deficiency.
11/2020	Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untreated, congenital isolated GH deficiency.
1/2019	Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to a GHRH Receptor Gene Mutation.
8/2017	MECHANISMS IN ENDOCRINOLOGY: The multiple facets of GHRH/GH/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation.
10/2016	Infectious diseases and immunological responses in adult subjects with lifetime untreated, congenital GH deficiency.
9/2014	Liver status in congenital, untreated, isolated GH deficiency.
11/2013	Isolated GH deficiency due to a GHRH receptor mutation causes hip joint problems and genu valgum, and reduces size but not density of trabecular and mixed bone.
8/2013	Prolactin and sex steroids levels in congenital lifetime isolated GH deficiency.
6/2013	Lifetime congenital isolated GH deficiency does not protect from the development of diabetes.
6/2007	Heterozygosity for a mutation in the growth hormone-releasing hormone receptor gene does not influence adult stature, but affects body composition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Viviane C Campos Research Topics

Disease

10	Pituitary Dwarfism 01/2021 - 06/2007
6	Insulin Resistance 01/2019 - 06/2007
4	Atherosclerosis 11/2020 - 12/2007
3	Infections 01/2021 - 10/2016
2	Hypopituitarism (Sheehan's Syndrome) 11/2020 - 01/2019
2	Leishmaniasis 01/2019 - 10/2016
2	Facies 01/2018 - 08/2017
2	Genu Valgum 08/2017 - 11/2013
1	COVID-19 01/2021
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2021
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 11/2020
1	CHARGE Syndrome 01/2018
1	Abdominal Obesity 08/2017
1	Sensorineural Hearing Loss 08/2017
1	Dizziness (Lightheadedness) 08/2017
1	Communicable Diseases (Infectious Diseases) 10/2016
1	Tetanus 10/2016
1	Hepatitis B 10/2016
1	Immune System Diseases (Immune Disorders) 10/2016
1	Non-alcoholic Fatty Liver Disease 09/2014
1	Glucose Intolerance 06/2013
1	Congenital Adrenal Hyperplasia (Hyperplasia, Congenital Adrenal) 02/2009

Drug/Important Bio-Agent (IBA)

10	somatotropin releasing hormone receptorIBA 01/2021 - 06/2007
6	Insulin-Like Growth Factor I (IGF-1)IBA 01/2019 - 06/2007
2	LDL CholesterolIBA 11/2020 - 08/2017
2	Hormones (Hormone)IBA 08/2017 - 01/2016
2	Growth Hormone (Somatotropin)IBA 10/2016 - 12/2007
2	Glucose (Dextrose)FDA LinkGeneric 06/2013 - 03/2012
1	AntibodiesIBA 01/2021
1	fibroblast growth factor 21IBA 01/2021
1	Pituitary HormonesIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 11/2020
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 11/2020
1	CalciumIBA 01/2019
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Retinaldehyde (Retinal)IBA 08/2017
1	AcidsIBA 08/2017
1	Insulin-Like Growth Factor Binding ProteinsIBA 08/2017
1	C-Reactive ProteinIBA 08/2017
1	Insulin-Like Growth Factor II (Somatomedin A)IBA 08/2017
1	Immunoglobulin G (IgG)IBA 10/2016
1	CreatinineIBA 01/2016
1	Transaminases (Aminotransferases)IBA 09/2014
1	SteroidsIBA 08/2013
1	ProlactinIBA 08/2013
1	Steroid 21-Hydroxylase (21 Hydroxylase)IBA 02/2009
1	Insulin (Novolin)FDA Link 06/2007

Therapy/Procedure

1	Radiotherapy 01/2021